Actively Recruiting
Speech-based Assessment of Relapse Risk in People With Psychosis
Led by Philipp Homan · Updated on 2026-02-09
360
Participants Needed
7
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This observational, multinational study assesses the feasibility of speech and self-report data collection across six languages for Artificial Intelligence (AI)-driven relapse risk estimation in psychosis. Over 12 months, patients at risk of relapse and healthy controls will provide weekly speech recordings and self-report data for automated analysis. Risk scores will be stored but not shared with treating clinicians. Independent clinical evaluations ensure data quality and validation. The study lays the foundation for future Clinical Decision Support System (CDSS) research and explores novel speech markers for relapse prediction while minimizing participant burden.
CONDITIONS
Official Title
Speech-based Assessment of Relapse Risk in People With Psychosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ages 18 to 65 years
- Ability to provide informed consent
- Signed informed consent prior to enrollment
- Native or equivalent fluency in English, German, Dutch, French, Czech, or Turkish
- Access to a smartphone and ability to use a mobile app for speech data collection
- Ability to comply with study schedule and procedures
- For healthy participants: no regular prescription drug use
- For individuals with psychosis: diagnosis of psychotic disorders including schizophrenia, schizoaffective disorder, schizophreniform disorder, acute psychosis, bipolar disorder with psychotic symptoms, or psychosis not otherwise specified
- For individuals with psychosis: first visit during remission phase
- For individuals with psychosis: mild or lower positive symptoms (score 3 or lower) on hallucinatory behavior, unusual thought content, and conceptual disorganization on BPRS
You will not qualify if you...
- For healthy participants: history of major diseases such as cardiovascular, neurological, metabolic, renal, hepatic, respiratory, or speech disorders
- For healthy participants: recreational drug use or psychiatric disorders due to alcohol use
- For healthy participants: depression, anxiety, or other psychiatric disorders
- For healthy participants: family history of depression, anxiety, or other psychiatric disorders
- For any participant: inability or unwillingness to understand study purpose and details
- For individuals with psychosis: severe speech disorders like aphasia or severe stuttering preventing adequate speech recording
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
National Institute of Mental Health
Klecany, Czechia, 250 67
Not Yet Recruiting
2
Newcastle Hospital and RCSI University of Medicine and Health Sciences
Greystones, Wicklow, Ireland, A63 CD30
Not Yet Recruiting
3
University Medical Center Groningen
Groningen, Netherlands, 9713
Not Yet Recruiting
4
The Arctic University of Norway
Tromsø, Norway, 9037
Active, Not Recruiting
5
University Hospital Geneva and University of Geneva
Geneva, Chêne-Bourg, Switzerland, 1225
Not Yet Recruiting
6
Psychiatric University Hospital Zurich and University of Zurich
Zurich, Switzerland, 8032
Actively Recruiting
7
Dokuz Eylul University
Izmir, Turkey (Türkiye)
Not Yet Recruiting
Research Team
P
Philipp Homan, Prof. Dr. med. univ. PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here